Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04817748

Acronym

MCBDTMIDT

Enrollment

Registered

2021-03-26

Start date

2020-11-17

Completion date

2021-05-01

Last updated

2021-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

myocardial infarction, metabolomics, biomarkers

Brief summary

To find new biomarkers through Metabonomics Study of different types of myocardial infarction in Different Time.

Detailed description

In recent years, with the deepening understanding of the mechanism of myocardial infarction, in addition to the early understanding of plaque rupture, plaque erosion and other mechanisms, studies have found that inflammation, immunity, metabolism and other factors also play an increasingly important role in the occurrence and development of myocardial infarction. The LoDoCo2 study published at the 2020 ESC annual meeting and the COLCOT study previously published confirmed for the first time the therapeutic effect of anti-inflammatory drug colchicine in chronic coronary disease and acute myocardial infarction. At the same time, the fourth international definition of myocardial infarction also defines three different types of acute ST segment elevation myocardial infarction (STEMI), acute non ST segment elevation myocardial infarction (NSTEMI) and non infarct acute myocardial infarction (MINOCA). However, there are no clear research results on the mechanism, especially the mechanism of MINOCA. Therefore, the study of acute myocardial infarction in three groups is of great significance.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 76 Years

Healthy volunteers

Yes

Inclusion criteria

1.The patient clearly had acute myocardial infarction. 2.The patient's serum cardiac markers (mainly troponin) were elevated (at least above the upper limit of 99% reference value) and accompanied by one of the following clinical indicators： 1. Ischemic symptoms 2. New ischemic ECG changes, new ST-T changes or left bundle branch block（LBBB）. 3. Pathological Q wave formation in ECG 4. Imaging evidence showed new loss of myocardial activity or new regional wall motion abnormalities. 5. The thrombus was confirmed by coronary angiography. 3．The patient had chest pain symptoms, but coronary angiography showed normal coronary artery (such as intercostal neuralgia, cervical spondylosis, chest pain of unknown origin, etc.)

Exclusion criteria

1. Refusal to sign informed consent. 2. Surgical treatment was performed in the last three months. 3. Patients with a history of the following diseases or consider the diagnosis of the following diseases：Stress cardiomyopathy, myocarditis, pericarditis, pneumonia, pulmonary embolism, aortic dissection. 4. Severe heart failure, grade IV cardiac function. 5. Liver and kidney dysfunction. 6. blood-borne diseases, including HIV / AIDS, hepatitis B, hepatitis C, etc. 7. Patients with a history of malignancies, autoimmune diseases, severe infectious diseases and trauma. 8. Previous history of myocardial infarction and stroke.

Design outcomes

Primary

Measure	Time frame	Description
metabolites molecules	6 months	Detection of small molecular metabolites in blood by liquid chromatography mass spectrometry and gas chromatography mass spectrometry

Countries

China

Contacts

Primary ContactYi Zhang, MD

yizshcn@gmail.com18917686332

Backup ContactZheng Liu, MD

18521526364@163.com18521526364

Outcome results